{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T13:40:08Z","timestamp":1783777208092,"version":"3.55.0"},"reference-count":33,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,11,25]],"date-time":"2022-11-25T00:00:00Z","timestamp":1669334400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004326","name":"Bayer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004326","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["esmoopen.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["ESMO Open"],"published-print":{"date-parts":[[2023,2]]},"DOI":"10.1016\/j.esmoop.2022.100748","type":"journal-article","created":{"date-parts":[[2023,1,3]],"date-time":"2023-01-03T16:34:44Z","timestamp":1672763684000},"page":"100748","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Regorafenib monotherapy as second-line treatment of patients with RAS-mutant advanced colorectal cancer (STREAM): an academic, multicenter, single-arm, two-stage, phase II study"],"prefix":"10.1016","volume":"8","author":[{"given":"C.","family":"Cardone","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"De Stefano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Rosati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Cassata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Silvestro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Borrelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Di Gennaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Romano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Nappi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Zanaletti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Foschini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Casaretti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Tatangelo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Lastoria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Raddi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Bilancia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"Granata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Setola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Petrillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Vitagliano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Gargiulo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Arenare","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Febbraro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Martinelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Ciardiello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Delrio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Budillon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.C.","family":"Piccirillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Avallone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.esmoop.2022.100748_bib1","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1002\/ijc.33588","article-title":"Cancer statistics for the year 2020: an overview","volume":"149","author":"Ferlay","year":"2021","journal-title":"Int J Cancer"},{"key":"10.1016\/j.esmoop.2022.100748_bib2","first-page":"145","article-title":"Colorectal cancer statistics, 2020","volume":"70","author":"Siegel","year":"2020","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.esmoop.2022.100748_bib3","doi-asserted-by":"crossref","first-page":"2643","DOI":"10.1158\/0008-5472.CAN-06-4158","article-title":"Oncogenic activation of the RAS\/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies","volume":"67","author":"Benvenuti","year":"2007","journal-title":"Cancer Res"},{"key":"10.1016\/j.esmoop.2022.100748_bib4","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1053\/j.gastro.2019.12.051","article-title":"Precision therapy in RAS mutant colorectal cancer","volume":"158","author":"Dienstmann","year":"2020","journal-title":"Gastroenterology"},{"key":"10.1016\/j.esmoop.2022.100748_bib5","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1093\/annonc\/mdw235","article-title":"ESMO consensus guidelines for the management of patients with metastatic colorectal cancer","volume":"27","author":"Van Cutsem","year":"2016","journal-title":"Ann Oncol"},{"key":"10.1016\/j.esmoop.2022.100748_bib6","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S1470-2045(12)70477-1","article-title":"Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial","volume":"14","author":"Bennouna","year":"2013","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.esmoop.2022.100748_bib7","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/j.ejca.2013.09.013","article-title":"Aflibercept versus placebo in combination with fluorouracil, leucovorin and irinotecan in the treatment of previously treated metastatic colorectal cancer: prespecified subgroup analyses from the VELOUR trial","volume":"50","author":"Tabernero","year":"2014","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.esmoop.2022.100748_bib8","doi-asserted-by":"crossref","first-page":"2342","DOI":"10.1093\/annonc\/mdt231","article-title":"Bevacizumab plus chemotherapy continued beyond first progression in patients with metastatic colorectal cancer previously treated with bevacizumab plus chemotherapy: ML18147 study KRAS subgroup findings","volume":"24","author":"Kubicka","year":"2013","journal-title":"Ann Oncol"},{"key":"10.1016\/j.esmoop.2022.100748_bib9","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1002\/ijc.25864","article-title":"Regorafenib (BAY 73-4506): a new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity","volume":"129","author":"Wilhelm","year":"2011","journal-title":"Int J Cancer"},{"key":"10.1016\/j.esmoop.2022.100748_bib10","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1002\/ijc.28669","article-title":"Regorafenib (BAY 73-4506): antitumor and antimetastatic activities in preclinical models of colorectal cancer","volume":"135","author":"Schmieder","year":"2014","journal-title":"Int J Cancer"},{"key":"10.1016\/j.esmoop.2022.100748_bib11","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/S0140-6736(12)61900-X","article-title":"Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial","volume":"381","author":"Grothey","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.esmoop.2022.100748_bib12","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1634\/theoncologist.2018-0072","article-title":"Regorafenib for patients with metastatic colorectal cancer who progressed after standard therapy: results of the large, single-arm, open-label phase IIIb CONSIGN study","volume":"24","author":"Van Cutsem","year":"2019","journal-title":"Oncologist"},{"key":"10.1016\/j.esmoop.2022.100748_bib13","doi-asserted-by":"crossref","first-page":"2062","DOI":"10.2967\/jnumed.113.119909","article-title":"Early PET\/CT scan is more effective than RECIST in predicting outcome of patients with liver metastases from colorectal cancer treated with preoperative chemotherapy plus bevacizumab","volume":"54","author":"Lastoria","year":"2013","journal-title":"J\u00a0Nucl Med"},{"key":"10.1016\/j.esmoop.2022.100748_bib14","first-page":"1079","article-title":"There are no bad anticancer agents, only bad clinical trial designs--twenty-first Richard and Hinda Rosenthal Foundation Award Lecture","volume":"4","author":"Von Hoff","year":"1998","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.esmoop.2022.100748_bib15","doi-asserted-by":"crossref","DOI":"10.1136\/esmoopen-2019-000583","article-title":"Community-driven development of a modified progression-free survival ratio for precision oncology","volume":"4","author":"Mock","year":"2019","journal-title":"ESMO Open"},{"key":"10.1016\/j.esmoop.2022.100748_bib16","doi-asserted-by":"crossref","first-page":"3538","DOI":"10.1200\/JCO.2017.35.15_suppl.3538","article-title":"Velour trial biomarkers update: impact of RAS, BRAF, and sidedness on aflibercept activity","volume":"35","author":"Wirapati","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.esmoop.2022.100748_bib17","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.1007\/s00432-020-03290-y","article-title":"Current treatment options in RAS\u00a0mutant metastatic colorectal cancer patients: a meta-analysis of 14\u00a0randomized phase III trials","volume":"146","author":"Stahler","year":"2020","journal-title":"J\u00a0Cancer Res Clin Oncol"},{"key":"10.1016\/j.esmoop.2022.100748_bib18","doi-asserted-by":"crossref","first-page":"3472","DOI":"10.1158\/1078-0432.CCR-13-2944","article-title":"Regorafenib inhibits colorectal tumor growth through PUMA-mediated apoptosis","volume":"20","author":"Chen","year":"2014","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.esmoop.2022.100748_bib19","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.canlet.2017.03.011","article-title":"Regorafenib overcomes chemotherapeutic multidrug resistance mediated by ABCB1 transporter in colorectal cancer: in\u00a0vitro and in\u00a0vivo study","volume":"396","author":"Wang","year":"2017","journal-title":"Cancer Lett"},{"key":"10.1016\/j.esmoop.2022.100748_bib20","first-page":"308","article-title":"Treatment of metastatic refractory colorectal cancer following regorafenib failure","volume":"7","author":"Takeuchi","year":"2017","journal-title":"Mol Clin Oncol"},{"key":"10.1016\/j.esmoop.2022.100748_bib21","first-page":"102","article-title":"Chemotherapy rechallenge after regorafenib treatment in metastatic colorectal cancer: still hope after the last hope?","volume":"29","author":"Bertocchi","year":"2017","journal-title":"J\u00a0Chemother"},{"key":"10.1016\/j.esmoop.2022.100748_bib22","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1186\/s12885-021-08890-6","article-title":"Second-line chemotherapy after early disease progression during first-line chemotherapy containing bevacizumab for patients with metastatic colorectal cancer","volume":"21","author":"Yamamoto","year":"2021","journal-title":"BMC Cancer"},{"key":"10.1016\/j.esmoop.2022.100748_bib23","doi-asserted-by":"crossref","DOI":"10.1136\/esmoopen-2017-000177","article-title":"Clinical outcome and molecular characterisation of chemorefractory metastatic colorectal cancer patients with long-term efficacy of regorafenib treatment","volume":"2","author":"Martinelli","year":"2017","journal-title":"ESMO Open"},{"key":"10.1016\/j.esmoop.2022.100748_bib24","doi-asserted-by":"crossref","DOI":"10.1136\/esmoopen-2019-000519","article-title":"Exploratory findings from a prematurely closed international, multicentre, academic trial: RAVELLO, a phase III study of regorafenib versus placebo as maintenance therapy after first-line treatment in RAS wild-type metastatic colorectal cancer","volume":"4","author":"Cardone","year":"2019","journal-title":"ESMO Open"},{"key":"10.1016\/j.esmoop.2022.100748_bib25","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.ejca.2019.09.015","article-title":"Safety and effectiveness of regorafenib in patients with metastatic colorectal cancer in routine clinical practice in the prospective, observational CORRELATE study","volume":"123","author":"Ducreux","year":"2019","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.esmoop.2022.100748_bib26","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1016\/S1470-2045(19)30272-4","article-title":"Regorafenib dose-optimisation in patients with refractory metastatic colorectal cancer (ReDOS): a randomised, multicentre, open-label, phase 2 study","volume":"20","author":"Bekaii-Saab","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.esmoop.2022.100748_bib27","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1007\/s40487-021-00173-1","article-title":"18F-FDG-PET\/CT as an imaging biomarker for regorafenib efficacy in metastatic colorectal cancer (JACCRO CC-12)","volume":"9","author":"Nakamura","year":"2021","journal-title":"Oncol Ther"},{"key":"10.1016\/j.esmoop.2022.100748_bib28","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1038\/nrd4389","article-title":"Drugging the undruggable RAS: mission possible?","volume":"13","author":"Cox","year":"2014","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.esmoop.2022.100748_bib29","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1038\/nrd.2016.139","article-title":"Direct small-molecule inhibitors of KRAS: from structural insights to mechanism-based design","volume":"15","author":"Ostrem","year":"2016","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.esmoop.2022.100748_bib30","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2021.100156","article-title":"Strategies to tackle RAS-mutated metastatic colorectal cancer","volume":"6","author":"Patelli","year":"2021","journal-title":"ESMO Open"},{"key":"10.1016\/j.esmoop.2022.100748_bib31","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/s13046-021-02225-w","article-title":"The path to the clinic: a comprehensive review on direct KRASG12C inhibitors","volume":"41","author":"Kwan","year":"2022","journal-title":"J\u00a0Exp Clin Cancer Res"},{"issue":"suppl 7","key":"10.1016\/j.esmoop.2022.100748_bib32","first-page":"S136","article-title":"315O - Sotorasib in combination with panitumumab in refractory KRAS G12C-mutated colorectal cancer: safety and efficacy for phase Ib full expansion cohort","volume":"33","author":"Kuboki","year":"2022","journal-title":"Ann Oncol"},{"issue":"suppl 7","key":"10.1016\/j.esmoop.2022.100748_bib33","first-page":"S808","article-title":"LBA24 - KRYSTAL-1: updated efficacy and safety of adagrasib (MRTX849) with or without cetuximab in patients with advanced colorectal cancer (CRC) harboring a KRASG12C mutation","volume":"33","author":"Klempner","year":"2022","journal-title":"Ann Oncol"}],"container-title":["ESMO Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702922003829?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702922003829?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T20:29:29Z","timestamp":1761856169000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2059702922003829"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2]]},"references-count":33,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,2]]}},"alternative-id":["S2059702922003829"],"URL":"https:\/\/doi.org\/10.1016\/j.esmoop.2022.100748","relation":{},"ISSN":["2059-7029"],"issn-type":[{"value":"2059-7029","type":"print"}],"subject":[],"published":{"date-parts":[[2023,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Regorafenib monotherapy as second-line treatment of patients with RAS-mutant advanced colorectal cancer (STREAM): an academic, multicenter, single-arm, two-stage, phase II study","name":"articletitle","label":"Article Title"},{"value":"ESMO Open","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.esmoop.2022.100748","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Author(s). Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}],"article-number":"100748"}}